Table 5.
Selected Key Adjuvant Studies
| Study | Treatment | 1 year survival (%) |
2 year survival (%) |
5 year survival (%) |
DFS (mo) |
Median Survival (mo) |
|---|---|---|---|---|---|---|
| GITSG (1985)232 N=43 |
Observe v. chemorad |
49 v. 63 |
15 v. 42 | 14 v. 4 | < 9 v. 16 |
11 v. 20 (p=.01) |
| EORTC 40891 (1999) N=218147 |
Observe v. Chemorad | 53 v. 65 | 23 v. 37 | 22 v. 25 | NR | 12.6 v. 17.1 (pancreas only, p=.099) |
| JHH retrospective N=452233 |
Observe v. Chemorad |
NR | 32 v 44 | 15.4 v. 20.4 | NR | 14.4 v. 21.2 P<.001 |
| ESPAC-1 (2004) N=289148 |
2 X 2 design Observe v. Chemo |
? v. 67 | ? v 38 | 11.v. 29 | chemoXRT-10.7 no chemoXRT 15.2 chemo 15.3 no chemo-9.4 |
16.9 v. 21.6 |
| CONKO-1 (2007) N=354144 |
Observe v. Chemo |
72 v 72 | 42 v. 47 | 11 v. 22 | 6.9 v. 13.4 (P<.001) | 20 v. 22 (p=.06) |
| RTOG-9704 (2008) N=538153, 234 |
Gem-5FU/XRT v. 5FU, 5FU/XRT |
69 v. 65 | 35 v. 39 | 20 v. 20 | NR | 20.6 v. 16.9 (P=.03) |
| ESPAC-3 (2009) N=1030145 |
Gem v 5FU |
70 v. 70 | 40 v. 40 | NR | 14.3 v. 14.1 | 23.6 v. 23 |
| JHH and Mayo Clinic Retrospective (2010) N=1272152 |
Observation v. chemorads | 58. v 80 | 34.6 v. 44.7 | 16.1 v. 22.3 | 15.5 v. 21.1 (P<.001) | |
| ACOSOG (2011) N=89154 |
5FU CI, IFN/cisplatin +XRT |
80 | 60 | NR | 14.1 | 25.4 |
| CapRI (2012) N=110156 |
5-FU/cis/XRT + IFN followed by 5FU v. 5FU | 85 v. 80 | 60 v. 55 | 25 v. 25 | 15.2 v. 11.5 (p=.61) | 32. 1 v. 28.5 (P=.49) |
ACOSOG=American College of Surgeons Oncology Group; CaPRI=Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma; CI=continuous infusion; CONKO=CharitéOnkologie; DFS= disease free survival; EORTC=European Organization for Research and Treatment of Cancer; ESPAC=European Study group for Pancreatic Cancer; 5-FU=5-fluorouracil; GITSG=Gastrointestinal Tumor Study Group; IFN= interferon; JHH=Johns Hopkins Hospital; RTOG=Radiation Therapy Oncology Group; XRT=external beam radiation therapy.